Anti-inflammatory properties of cryptolepine

Phytotherapy Research

Volumn 23, Issue 10, 2009, Pages 1421-1425

  Olajide, Olumayokun A ^a,d   Ajayi, Abayomi M ^a,c   Wright, Colin W ^b  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c KAMPALA INTERNATIONAL UNIVERSITY   (Uganda)

^d Narolag Phytopharm Services   (United Kingdom)

Author keywords

Anti inflammatory; Carrageenan; Cryptolepine; Lipopolysaccharide

Indexed keywords

ACETIC ACID; CARRAGEENAN; CRYPTOLEPINE; INDOMETACIN; LIPOPOLYSACCHARIDE; N(G) NITROARGININE METHYL ESTER;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DOSE RESPONSE; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PAW EDEMA; PLEURISY; RAT; STOMACH LESION; WRITHING TEST;

ACETIC ACID; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR, ANIMAL; CAPILLARY PERMEABILITY; CARRAGEENAN; CRYPTOLEPIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; INDOLE ALKALOIDS; INDOMETHACIN; LIPOPOLYSACCHARIDES; MALE; PAIN; PHYTOTHERAPY; PLANT EXTRACTS; PLEURISY; QUINOLINES; RATS; RATS, WISTAR;

ANIMALIA; CRYPTOLEPIS SANGUINOLENTA; MUS; RATTUS;

EID: 70349899264     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2794     Document Type: Article

References (32)

1. Aparicio L. 1979. Some aspects of the pharmacology of butifen, a non steroidal anti - inflammatory agent. Arch Int Pharmacodyn Ther 227: 130-141. (Pubitemid 8160325)
2. Bamgbose SO, Noamesi BK. 1981. Studies on cryptolepine. II: Inhibition of carrageenan-induced oedema by cryptolepine. Planta Med 41: 392-396.
3. Berkenkopf JW, Weichman BM. 1988. Production of prostacyclin in mice following intraperitoneal injection of acetic acid, phenylbenzoquinone and zymosan: its role in the writhing response. Prostaglandins 36: 693-709.
4. Bierer DE, Fort DM, Mendez CD, Luo J, Imbach PA, Dubenko LG, Jolad SD, Gerber RE, Litvak J, Lu Q, Zhang P, Reed MJ, Waldeck N, Bruening RC, Noamesi BK, Hector RF, Carlson TJ, King SR. 1998. Ethnobotanical directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from Cryptolepis sanguinolenta, synthesis, and in vitro and in vivo activities. J Med Chem 41: 894-901.
5. Cimanga K, DeBruye T, Pieters L, Vlietrinck AJ. 1997. In vitro and in vivo antiplasmodial activity of Cryptolepine and related alkaloid from Cryptolepis sanguinolenta. J Nat Prod 60: 688-691.
6. Crunkhon P, Meacock SER. 1971. Mediators of the inflammation induced in the rat paw by carrageenan. Br J Pharmacol 42: 392-402.
7. Fujii E, Yoshioka T, Ishida H, Irie K, Muraki T. 2000. Evaluation of INOS dependent and independent mechanisms of the microvascular permeability change induced by lipopolysaccharide. Br J Pharmacol 130: 90-94. (Pubitemid 30248430)
8. Hess SM, Milonig RC. 1972. Assay for anti- inflammatory agents: In Inflammation: Mechanisms and control. Lepow IH, Ward PA (eds). New York Academic Press: New York; 1-12.
9. Ialenti A, Ianaro A, Moncada S, Di Rosa M. 1992. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 211: 177-182.
10. Irie K, Fujii E, Ishida H, Wada K, Suganuma T, Nishikori T, Yoshioka T, Muraki T. 2001. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. BrJ of Pharmacol 133: 237-242. (Pubitemid 32507042)
11. Kirby GC, Paine A, Warhurst DC, Noamesi BK, Phillipson JD. 1995. In vitro and in vivo antimalarial activity of cryptolepine, a plant-derived indoloquinoline. Phytother Res 9: 359-363.
12. Koster R, Anderson M, DeBeer EJ. 1959. Acetic acid for analgesic screening. Fed Proc 18: 412.
13. Laupattarakasem P, Wangsrimongkol T, Surarit R, Hahnvajanawong C. 2006. In vitro and in vivo anti-inflammatory potential of Cryptolepis buchanani. J Ethnopharmacol 108: 349-354.
14. Main AIH, Whittle BJR. 1975. Investigation of the vasodilatory and antisecretory role of prostaglanding in the rat gastric mucosa by use of non-steroidal anti-inflammatory drugs. Br J Pharmacol 53: 217-224.
15. Mikami T, Miyasaka K. 1983. Effects of several anti-inflammatory drugs on the various parameters involved in the inflammatory response in rat carrageenan-induced pleurisy. Eur J Pharmacol 95: 1-12. (Pubitemid 14248265)
16. Miranda HF, Sliva E, Pinardi G. 2004. Synergy between the antinociceptive effects of morphine and NSAIDs. Can J Physiol Pharmacol 82: 331-338.
17. NIH. 1985. Guide for the use of laboratory animals DHHS, PHS, NIH Publication No. 85: 23.
18. Olajide OA, Awe SO, Makinde JM, Ekhelar AI, Olusola A, Morebise O, Okapko DT. 2000. Studies on the antiinflammatory, antipyretic and analgesic properties of Alstonia boonei stem bark. J Ethnopharmacol 71: 179-186. (Pubitemid 30440667)
19. Olajide OA, Heiss EH, Schachner D, Wright C, Vollmar AM, Dirsch VM. 2007. Synthetic cryptolepine inhibits DNA binding of NF-κB. Bioorg Med Chem 15: 43-49. (Pubitemid 44738596)
20. Omisore NOA, Adewunmi CO, Iwalewa EO, Ngadjui BT, Watchueng J, Abegaz BM, Ojewole JAO. 2004. Antinociceptive and anti-inflammatory effects of Dorstenia barteri (Moraceae) leaf and twig extracts in mice. J Ethnopharmacol 95: 7-12. (Pubitemid 39221404)
21. Oyekan AO, Ablordeppey SY. 1993. Effects of cryptolepine on collagen-induced aggregation and on the mobilization and metabolism of arachidonic acid by rabbit platelets. Gen Pharmacol 24: 1285-1290. (Pubitemid 23283103)
22. Oyekan AO, Botting JH, Noamesi BK. 1988. Cryptolepine inhibits platelet aggregation in vitro and in vivo and stimulates fibrinolysis ex vivo. Gen Pharmacol 19: 233-237. (Pubitemid 18060146)
23. Oyekan AO, Okafor JP. 1989. Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. J Ethnopharmacol 27: 141-148.
24. Paulo A, Pimentel M, Viegas S, Pires I, Cabrita J, Gomes ET. 1994. Cryptolepis sanguinolenta activity against diarrhoeal bacteria. J Ethnopharmacol 44: 73-77. (Pubitemid 24330224)
25. Ribeiro RA, Vale ML, Thomazzi SM, Paschoalato AB, Poole S, Ferreira SH, Cunha FQ. 2000. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. Eur J Pharmacol 387: 111-118. (Pubitemid 30035382)
26. Sakaguchi Y, Shirahase H, Kunishiro K, Ichikawa A, Kanda M, Uehara Y. 2006. Effect of combination of nitric oxide synthase and cyclooxygenase inhibitors on carrageenan - induced pleurisy in rats. Life Sci 79: 442-447. (Pubitemid 43866125)
27. Sawer IK, Berry MI, Brown MW, Ford JL. 1995. The effect of Cryptolepine on the morphology and survival of Escherichia coli, Candida albicans and Saccharomyces cerevisae. J Appl Bact 79: 314-321.
28. Sugiyama Y, Kato S, Abe M, Mitsufuji S, Takeuchi K. 2005. Different effects of dexamethasone and the nitric oxide synthase inhibitor L-NAME on caerulein - induced rat acute pancreatitis, depending on the severity. Inflammopharmacol 13: 291-301.
29. Vinegar R, Truax JF, Selph JL, Voelker FA. 1982. Pathway of onset development and decay of carrageenan pleurisy in the rat. Fed Proc 41: 2588-2595. (Pubitemid 12061031)
30. Winter CA, Risley EA, Nuss CW. 1962. Carrageenan - induced oedema in the hind paw of the rat as an assay for anti-inflammatory drugs. Proc Soc Exp Biol Med 111: 544-547.
31. Wright CW, Phillipson JD, Awe SO, Kirby GC, Warhurst DC, Quetin-Leclerq J, Angenot L. 1996. Antimalarial activity of cryptolepine and some other anhydronium bases. Phytother Res 10: 361-363. (Pubitemid 26195883)
32. Wright CW, Addae-Kyereme J, Breen AG, Brown JE, Cox MF, Croft SL, Gokcek Y, Kendrick H, Phillips RM, Pollet PL. 2001. Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. J Med Chem 44: 3187-3194. (Pubitemid 32862349)